Company profile: Telesta Therapeutics
1.1 - Company Overview
Company description
- Provider of transformative human therapeutics, focused on licensing, acquisition, development, manufacturing and commercialization of novel medicines addressing major unmet medical needs, particularly in oncology; anchor product MCNA has completed a Phase III pivotal study.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Telesta Therapeutics
Leap Therapeutics
HQ: United States
Website
- Description: Provider of targeted and immuno-oncology therapeutics in clinical development, including DKN-01 (monoclonal antibody against DKK1 for esophagogastric, gynecologic, colorectal, prostate, and lung cancers), FL-301 (monoclonal antibody against Claudin18.2 for gastric and pancreatic cancers), FL-302 (tetravalent bispecific targeting Claudin18.2 and CD137 to enhance T-cell activation), and FL-501 (designed to neutralize GDF15 to prevent cachexia and inhibit immunosuppressive tumor micro-environment in various cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leap Therapeutics company profile →
Flexus BioSciences
HQ: United States
Website
- Description: Provider of novel anti-cancer therapeutics created, developed, and commercialized through an innovative application of unexploited insights in immunology; privately-held biopharmaceutical company founded in 2013 and headquartered in San Carlos, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flexus BioSciences company profile →
Lassen Therapeutics
HQ: United States
Website
- Description: Provider of antibody biotherapeutics, developing monoclonal antibodies including LASN01, which targets the IL-11 receptor to treat fibro-inflammatory diseases such as thyroid eye disease and idiopathic pulmonary fibrosis, and LASN500, which targets IL-18 binding protein to elevate IL-18 at the tumor site for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lassen Therapeutics company profile →
Atlab Pharma
HQ: France
Website
- Description: Provider of antibody-targeted anti-cancer drugs and radioimmunotherapy, developing monoclonal antibody-radioisotope conjugates to deliver tumor-specific radiation to cancer cells wherever they have disseminated in the body.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atlab Pharma company profile →
Dynavax
HQ: United States
Website
- Description: Provider of biopharmaceutical products to prevent infectious diseases, including HEPLISAV-B, an adult hepatitis B vaccine designed to prevent infection by all known subtypes of the virus, and CpG 1018, an adjuvant used in vaccines to enhance the immune response and contained in the HEPLISAV-B hepatitis B vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dynavax company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Telesta Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Telesta Therapeutics
2.2 - Growth funds investing in similar companies to Telesta Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Telesta Therapeutics
4.2 - Public trading comparable groups for Telesta Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →